Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a biologic allergen extract combining pollen from Juniperus oxycedrus (prickly juniper) and Cupressus arizonica (Arizona cypress), two plants in the Cupressaceae family. It is being developed as an in-house reference preparation for standardizing allergy diagnostic tests, specifically skin prick tests. [3-1, 3-2] The product is intended for the diagnosis of inhalant allergies such as rhinitis, rhinoconjunctivitis, and/or asthma in patients with a clinical history of sensitivity to these pollens. [3-13, 4-23] It works by targeting the immune system, specifically triggering an IgE-mediated response upon intradermal administration in sensitized individuals, allowing for the confirmation of an allergy. Due to significant cross-reactivity within the Cupressaceae family, individuals allergic to one species often react to others.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juniperus oxycedrus allergen extract + cupressus arizonica allergen extract.